SDZ NKT 343 is a selective, orally activeNK₁receptorantagonist with anIC₅₀of 0.62 nM against human NK₁receptor. SDZ NKT 343 has good analgesic activity^[1][2].

SDZ NKT 343 shows a markedly lower affinity at rat NK₁receptors in whole forebrain membranes (IC₅₀=451+139 nM)^[1].
SDZ NKT 343 shows weak affinity to human NK₂and NK₃receptors in transfected Cos-7 cells (K_iof 0.52+0.04 μM and 3.4+1.2 μM respectively)^[1].

SDZ NKT 343 antagonized [Sar⁹]SP sulphone-evoked bronchoconstriction (70% reduction at 0.4 mg/kg, i.v.) in anaesthetized guinea-pigs^[1].

579.65

C₃₃H₃₃N₅O₅

180046-99-5

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.